Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques

This publication has 27 references indexed in Scilit:

• Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection
  British Journal of Cancer, 2000
• Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interkukin-2 in peripheral blood lymphocytes
  Annals of Oncology, 1999
• In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial
  Human Gene Therapy, 1999
• Cancer vaccines
  Nature Medicine, 1998
• Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant Mesothelioma
  Human Gene Therapy, 1998
• A Phase I Study of Recombinant Adenovirus Vector-Mediated Intraperitoneal Delivery of Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene and Intravenous Ganciclovir for Previously Treated Ovarian and Extraovarian Cancer Patients. University of Alabama Comprehensive Cancer Center, Birmingham, AL
  Human Gene Therapy, 1997
• Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
  Urology, 1995
• Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma
  European Journal Of Cancer, 1994
• 31P-NMR STUDIES OF A HUMAN TUMOUR IN SITU
  The Lancet, 1983
• 31P-NMR investigation of solid tumours in the living rat
  Bioscience Reports, 1981